DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

MM de Souza, AR Cenci, KF Teixeira… - Current Medicinal …, 2023 - ingentaconnect.com
Background: Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most
common form of dementia, especially in the elderly. Due to the increase in life expectancy, in …

DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective

A Pathak, A Rohilla, T Gupta, MJ Akhtar… - European Journal of …, 2018 - Elsevier
Alzheimer, the fourth leading cause of death embodies a key responsible event including
formation of β-amyloid protein clustering to amyloid plaque on blood vessels. The origin of …

Treatment of Alzheimer's Disease: Contemporary Perspectives in Medicinal Chemistry

AS de Oliveira - Current Medicinal Chemistry, 2023 - ingentaconnect.com
Alzheimer's disease (AD) is a neurodegenerative disease that causes the loss of cognitive
functions, such as memory, orientation, attention, and language. This loss of brain function …

DYRK1A inhibition as potential treatment for Alzheimer's disease

S Stotani, F Giordanetto, F Medda - Future medicinal chemistry, 2016 - Taylor & Francis
In total, 47,500,000 people worldwide are affected by dementia and this number is estimated
to double by 2030 and triple within 2050 resulting in a huge burden on public health …

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

B Smith, F Medda, V Gokhale… - ACS chemical …, 2012 - ACS Publications
With 24.3 million people affected in 2005 and an estimated rise to 42.3 million in 2020,
dementia is currently a leading unmet medical need and costly burden on public health …

DYRK1A inhibitors for disease therapy: Current status and perspectives

T Liu, Y Wang, J Wang, C Ren, H Chen… - European journal of …, 2022 - Elsevier
Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a conserved
protein kinase that plays essential roles in various biological processes. It is located in the …

[HTML][HTML] Identification and analysis of a selective DYRK1A inhibitor

TE Lin, MW Chao, WC HuangFu, HJ Tu… - Biomedicine & …, 2022 - Elsevier
The dysregulation of DYRK1A is implicated in many diseases such as cancer, diabetes, and
neurodegenerative diseases. Alzheimer's disease is one of the most common …

Selective DYRK1A inhibitor for the treatment of neurodegenerative diseases: Alzheimer, parkinson, huntington, and down syndrome

RB Kargbo - ACS medicinal chemistry letters, 2020 - ACS Publications
Biological Target. Dual specificity tyrosine phosphorylation regulated kinase-1 A (DYRK1A).
Summary. Alzheimer, s disease (AD) is the primary cause of dementia in the elderly, and the …

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics

DB Jarhad, KK Mashelkar, HR Kim… - Journal of medicinal …, 2018 - ACS Publications
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a member of an
evolutionarily conserved family of protein kinases that belongs to the CMGC group of …

Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation

N Qiu, C Qian, T Guo, Y Wang, H Jin, M Yao… - International Journal of …, 2024 - Elsevier
Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) plays an essential
role in Tau and Aβ pathology closely related to Alzheimer's disease (AD). Accumulative …